Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 236 clinical trials
Featured trial
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.  

bladder cancer
metastatic urothelial carcinoma
urothelial carcinoma
bladder carcinoma
  • 243 views
  • 10 May, 2022
  • 64 locations
Featured trial
Avelumab in UroThelIal CarcInoma-PATRIOIT-II

People with Urothelial Carcinoma are asked to participate in a research study being conducted by Montefiore Medical Center.

  • 0 views
  • 06 Aug, 2021
  • 1 location
Featured trial
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (516-003)

This is a study involving an investigational (experimental) drug called sitravatinib, given in combination with the immunotherapy nivolumab (also known as OPDIVO®).  Sitravatinib is designed to block specific proteins that are thought to cause tumors to grow and to prevent growth of new blood vessels that help cancer tumors to …

cancer
platinum-based chemotherapy
tumor cells
metastatic urothelial carcinoma
nivolumab
  • 86 views
  • 02 Jun, 2021
  • 1 location
Featured trial
CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

  • 176 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

advanced cancer
cancer
  • 226 views
  • 10 May, 2022
  • 4 locations
Featured trial
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.  This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose …

metastatic cervical cancer
carcinoma
ovarian cancer
urothelial carcinoma
  • 380 views
  • 10 May, 2022
  • 4 locations
Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma

The aim of this study is to explore efficacy and safety of neoadjuvant nivolumab for non-metastatic upper tract urothelial carcinoma (UTUC), and explore the potential predictive biomarkers of

  • 0 views
  • 22 Dec, 2021
  • 1 location
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with previously untreated advanced (metastatic or recurrent) urothelial carcinoma who are chemotherapy ineligible or who

  • 19 views
  • 05 Oct, 2021
  • 1 location
Combination Therapy With Pembrolizumab and sEphB4-HSA in Previously Treated Urothelial Carcinoma

This phase II trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with urothelial (bladder) cancer that has spread from the primary site to other places in the body or has come back and does not respond to certain chemotherapy drugs. Combinations of biological substances …

  • 3 views
  • 24 Feb, 2022
  • 2 locations
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or metastatic urothelial cancer who are not candidates to receive a platinum-based treatment …

  • 18 views
  • 21 Apr, 2022
  • 17 locations